Inogen Inc is a medical technology business that focuses on respiratory health. It develops, manufactures, and markets respiratory health products, including portable oxygen concentrators, or POCs, used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions and the Simeox product for airway clearance treatment. In addition, it has started distributing the Inogen Voxi 5 stationary oxygen concentrator as well as the Aurora continuous positive airway pressure, or CPAP, masks in the United States. The company derives revenues from customers through the development, manufacturing, marketing, sales, and rental of respiratory products.
Last trade$5.68
Day change+$0.05 (+0.89%)
Day range$5.52 – $5.79
Volume80,502
Market cap$146M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$146.39M
Price / earnings
—
Price / book
0.93×
Price / sales
0.43×
EV / sales
0.19×
EV / EBITDA
-3.77×
Profitability
Earnings per share
-$1.36
Return on assets
-13.38%
Return on equity
-22.59%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
2.96×
Quick ratio
2.55×
Cash ratio
1.16×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$13.44M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for INGN, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$77.19M
$95.08M
$85.11M
$81.72M
$79.09M
$92.28M
$82.28M
$80.08M
Cost of revenue
$43.19M
$51.81M
$47.25M
$46.49M
$42.93M
$50.94M
$45.91M
$43.79M
Gross profit
$34.01M
$43.27M
$37.86M
$35.24M
$36.17M
$41.34M
$36.37M
$36.29M
Selling, general and administrative
$33.63M
$42.5M
$42.1M
$39.23M
$36.76M
$42.26M
$39.99M
$41.78M
Research and development
$5.4M
$5.87M
$5.1M
$5.32M
$4.84M
$5.21M
$4.03M
$5.9M
Total operating expenses
$49.59M
$48.37M
$47.2M
$44.54M
$41.6M
$47.47M
$44.03M
$47.68M
Operating income
-$15.58M
-$5.1M
-$9.34M
-$9.31M
-$5.44M
-$6.13M
-$7.66M
-$11.39M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$14.64M
-$4M
-$8.5M
-$7.36M
-$3.76M
-$4.31M
-$6.27M
-$10.09M
Income taxes
$153K
-$154K
-$174K
-$236K
-$146K
-$153K
-$97K
-$330K
Net income
-$16.16M
-$3.85M
-$8.32M
-$7.13M
-$5.29M
-$4.15M
-$6.17M
-$9.76M
Net income attributable to common shareholders
-$16.16M
-$3.85M
-$8.32M
-$7.13M
-$5.29M
-$4.15M
-$6.17M
-$9.76M
EBITDA
-$8.02M
-$399K
-$4.43M
-$4.27M
-$9.23M
-$913K
-$2.47M
-$6.31M
Basic earnings per share
-$0.61
-$0.14
-$0.30
-$0.26
-$0.20
-$0.15
-$0.25
-$0.41
Diluted earnings per share
-$0.61
-$0.14
-$0.30
-$0.26
-$0.20
-$0.15
-$0.25
-$0.41
Recent news
Company coverage with links to the original publishers.
Inogen reported Q3 2026 results showing mixed performance with U.S. sales growth of 3.8% driven by new products, but international sales declined 9% due to European customer softness. The company divested its U.S. oxygen rental business for $24.8 million and announced a $20 million cost-reduction program to accelerate profitability. New CEO Andrew Reding outlined plans to streamline operations and expand into adjacent respiratory markets with Aurora and Voxi products. Full-year revenue guidance is $298-301 million with adjusted net loss of $7-8 million.
The global oxygen therapy equipment market is expected to grow from ~$3 billion in 2024 to ~$6 billion by 2032, driven by rising respiratory disorders, increased critical care utilization, and technological advancements in oxygen delivery systems.
The US Durable Medical Equipment Market is projected to grow at 5.03% CAGR from 2025-2033, reaching $97.10 billion, driven by aging population, chronic diseases, and home healthcare demand, with technological advances and market expansion opportunities.
Tosyalı, a major global green steel producer, is expanding its renewable energy efforts by signing an agreement with GE Vernova and Inogen for the first 120 MWp of its 1.2 GW solar self-consumption project in Türkiye. The project will use locally produced Tosyalı V-Solar panels and aims to meet around 50% of Tosyalı's energy needs through solar power.
Tosyalı, a leading global green steel producer, is investing in a 1.2 GW self-consumption solar power plant project in Turkey. The project will utilize Tosyalı's locally produced solar panels and is being developed in partnership with GE Vernova and Inogen. The project aims to meet around 50% of Tosyalı's energy needs from solar power, strengthening its position as a green steel producer.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.